3
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
CNS
1
Conditions
Glioblastoma
473
Brain Neoplasms
306
Glioma
257
Neoplasms
122
Astrocytoma
88
Carcinoma, Non-Small-Cell Lung
77
Breast Neoplasms
70
Neuroblastoma
65
Central Nervous System Neoplasms
61
Melanoma
58
Recurrence
46
Lung Neoplasms
45
Pancreatic Neoplasms
41
Oligodendroglioma
37
Ovarian Neoplasms
36
Colorectal Neoplasms
36
Neoplasm Metastasis
33
Sarcoma
32
Medulloblastoma
28
Stomach Neoplasms
27
Gliosarcoma
27
Lymphoma
25
Prostatic Neoplasms
24
Head and Neck Neoplasms
24
Neurofibromatosis 1
23
Rhabdomyosarcoma
21
Neurofibroma, Plexiform
19
Esophageal Neoplasms
19
Diffuse Intrinsic Pontine Glioma
19
Cholangiocarcinoma
19
Interventions
vorasidenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Disease Attributes
×
CNS
×
Clear all
NCT05592743
2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing